person · Reporting owner

BJERKHOLT ERIC

Disclosed activity across 9 companies

Tapewire entity: 24148
SEC CIK: 0001197350

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CERUS CORPCERS · Entity 5431	Director	June 09, 2026	June 12, 2026
CalciMedica, Inc.CALC · Entity 7804	Director	August 27, 2024	August 28, 2024
Metagenomi Therapeutics, Inc.MGX · Entity 7270	Director	June 09, 2026	June 11, 2026
Mirum Pharmaceuticals, Inc.MIRM · Entity 2416	CHIEF FINANCIAL OFFICER	September 11, 2026	September 15, 2026
Surrozen, Inc./DESRZN · Entity 6092	Director	May 13, 2026	May 14, 2026
Viracta Therapeutics, Inc.SNSS · Entity 85616	EVP, CFO & Corp. Secretary	November 30, 2016	December 06, 2016

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CERUS CORP

Report date June 09, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	261,679	Reported balance After 2026-06-09 transaction · row 1 1 source row Row 1 · 2026-06-09 · Sale · Disposed 20,454 · Balance 261,679

CalciMedica, Inc.

Report date August 27, 2024 · Filed August 28, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2034-08-26	Direct	10,000	Reported balance After 2024-08-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-08-27 · Grant · Acquired 10,000 · Balance 10,000 F1: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 28, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 28, 2024.

Metagenomi Therapeutics, Inc.

Report date June 09, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2036-06-08	Direct	21,000	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 21,000 · Balance 21,000 F1: The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date.

Mirum Pharmaceuticals, Inc.

Report date September 11, 2026 · Filed September 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	44,745	Ending reported balance After 2026-09-14 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-09-11 · Exercise / conversion · Acquired 18,333 · Balance 54,688 F1: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Row 2 · 2026-09-14 · Sale · Disposed 9,943 · Balance 44,745 F2: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-09-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-09-11 · Exercise / conversion · Disposed 18,333 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F3: The restricted stock units vest in a series of three successive equal annual installments beginning on the one-year anniversary of September 11, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).

F2: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

F3: The restricted stock units vest in a series of three successive equal annual installments beginning on the one-year anniversary of September 11, 2023.

Surrozen, Inc./DE

Report date May 13, 2026 · Filed May 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.14 · Expires 2036-05-12	Direct	5,550	Reported balance After 2026-05-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-13 · Grant · Acquired 5,550 · Balance 5,550 F1: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

Filing footnotes · ownership attribution and instrument terms

F1: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

Viracta Therapeutics, Inc.

Report date November 30, 2016 · Filed December 06, 2016 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2026-11-30	Direct	95,000	Reported balance After 2016-11-30 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2016-11-30 · Grant · Acquired 95,000 · Balance 95,000 F1: Twenty-five per cent (25%) of the total shares vest on November 30, 2017 and the remainder will vest ratably on each monthly anniversary thereafter such that the award will be fully vested on November 30, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: Twenty-five per cent (25%) of the total shares vest on November 30, 2017 and the remainder will vest ratably on each monthly anniversary thereafter such that the award will be fully vested on November 30, 2020.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Aimmune Therapeutics, Inc.

Report date October 10, 2020 · Filed October 14, 2020

Section 16 reporting ended · disclosed 2020-10-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, $0.0001 par valueSEC Table I · non-derivative	Direct	Reported balance After 2020-10-10 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2020-10-10 · Other · Disposed 27,805 · Balance 0 F1: Includes 1,869 shares acquired pursuant to the Issuer's employee stock purchase plan.
Common Stock, $0.0001 par valueSEC Table I · non-derivative	Direct	Reported balance After 2020-10-13 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2020-10-13 · Disposition to issuer · Disposed 23,905 · Balance 0 F2: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price"). F3: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.44	Direct	Reported balance After 2020-10-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-10-13 · Disposition to issuer · Disposed 264,800 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.07	Direct	Reported balance After 2020-10-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-10-13 · Disposition to issuer · Disposed 56,250 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.72	Direct	Reported balance After 2020-10-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-10-13 · Disposition to issuer · Disposed 78,750 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.81	Direct	Reported balance After 2020-10-13 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-10-13 · Disposition to issuer · Disposed 56,250 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 1,869 shares acquired pursuant to the Issuer's employee stock purchase plan.

F2: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price").

F3: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.

F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

CHINOOK THERAPEUTICS, INC.

Report date August 11, 2023 · Filed August 11, 2023

Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-08-11 transaction · row 1 1 source row Row 1 · 2023-08-11 · Disposition to issuer · Disposed 39,371 · Balance 0 F1: The number of shares reported includes 504 shares of the Issuer's Common Stock acquired, since that date of the reporting person's previous Form 4 filing, pursuant to the Issuer's employee stock purchase plan in transactions exempt from reporting under Rules 16b-3(c) and 16b-3(d). F2: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.98 · Expires 2030-11-29	Direct	Reported balance After 2023-08-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-08-11 · Disposition to issuer · Disposed 144,787 · Balance 0 F3: This stock option award, which provided for 25% of the award to vest on November 30, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.14 · Expires 2031-02-09	Direct	Reported balance After 2023-08-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-08-11 · Disposition to issuer · Disposed 21,501 · Balance 0 F4: This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.90 · Expires 2032-01-31	Direct	Reported balance After 2023-08-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-08-11 · Disposition to issuer · Disposed 88,000 · Balance 0 F5: This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.27 · Expires 2033-01-30	Direct	Reported balance After 2023-08-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-08-11 · Disposition to issuer · Disposed 84,000 · Balance 0 F6: This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-08-11 · Disposition to issuer · Disposed 16,415 · Balance 0 F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F8: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on November 30, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-08-11 · Disposition to issuer · Disposed 2,435 · Balance 0 F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F9: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-08-11 · Disposition to issuer · Disposed 14,667 · Balance 0 F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F10: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-08-11 · Disposition to issuer · Disposed 21,000 · Balance 0 F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F11: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-08-11 · Disposition to issuer · Disposed 8,400 · Balance 0 F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F12: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the performance-based RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

Filing footnotes · ownership attribution and instrument terms

F1: The number of shares reported includes 504 shares of the Issuer's Common Stock acquired, since that date of the reporting person's previous Form 4 filing, pursuant to the Issuer's employee stock purchase plan in transactions exempt from reporting under Rules 16b-3(c) and 16b-3(d).

F2: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.

F3: This stock option award, which provided for 25% of the award to vest on November 30, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F4: This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F5: This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F6: This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement.

F8: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on November 30, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

F9: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

F10: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

F11: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

F12: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the performance-based RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

Corium International, Inc.

Report date November 27, 2018 · Filed November 29, 2018

Section 16 reporting ended · disclosed 2018-11-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy The Bjerkholt Family Irrevocable Trust	Reported balance After 2018-11-27 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2018-11-27 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR").
Common StockSEC Table I · non-derivative	IndirectBy The Bjerkholt Children's Irrevocable Trust	Reported balance After 2018-11-27 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-11-27 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR").
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.97 · Expires 2025-04-13	Direct	Reported balance After 2018-11-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-11-27 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.19 · Expires 2025-12-17	Direct	Reported balance After 2018-11-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-11-27 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2026-12-21	Direct	Reported balance After 2018-11-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-11-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.59 · Expires 2027-11-30	Direct	Reported balance After 2018-11-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-11-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR").

F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 14, 2026 Filed Sep 15, 2026 20:10 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	9,943	$98.37	$978,092.91	Disclosure SEC source: 0001197350-26-000010 · form4-09152026_040901.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,745 F2 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document
September 11, 2026 Filed Sep 15, 2026 20:10 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionRestricted Stock Units · Derivative	18,333	$0.00	$0.00	Disclosure SEC source: 0001197350-26-000010 · form4-09152026_040901.xml · derivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F3 · derivative.exercise_date: The restricted stock units vest in a series of three successive equal annual installments beginning on the one-year anniversary of September 11, 2023. F3 · derivative.expiration_date: The restricted stock units vest in a series of three successive equal annual installments beginning on the one-year anniversary of September 11, 2023. Read SEC document
September 11, 2026 Filed Sep 15, 2026 20:10 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	18,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001197350-26-000010 · form4-09152026_040901.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Read SEC document
August 11, 2026 Filed Aug 12, 2026 21:14 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	6,001	$99.90	$599,509.50	Disclosure SEC source: 0001197350-26-000009 · form4-08122026_090835.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,355 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026. F2 · price: . The weighted average sale price for the transaction reported was $99.901633, and the range of prices were between $99.90 and $99.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · balance_after: Includes 175 shares of common stock that were acquired by the Reporting Person on May 10, 2026, pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document
July 06, 2026 Filed Jul 8, 2026 21:07 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	300	$124.94	$37,482.00	Disclosure SEC source: 0001197350-26-000008 · form4-07082026_090727.xml · nonDerivative · entry 4 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,181 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026. Read SEC document
July 06, 2026 Filed Jul 8, 2026 21:07 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	528	$123.84	$65,387.52	Disclosure SEC source: 0001197350-26-000008 · form4-07082026_090727.xml · nonDerivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,481 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026. F4 · price: . The weighted average sale price for the transaction reported was $123.84, and the range of prices were between $123.285 and $124.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document
July 06, 2026 Filed Jul 8, 2026 21:07 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	1,048	$122.43	$128,306.64	Disclosure SEC source: 0001197350-26-000008 · form4-07082026_090727.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,009 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026. F3 · price: . The weighted average sale price for the transaction reported was $122.43, and the range of prices were between $122.235 and $123.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document
July 06, 2026 Filed Jul 8, 2026 21:07 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	3,124	$121.67	$380,097.08	Disclosure SEC source: 0001197350-26-000008 · form4-07082026_090727.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,057 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026. F2 · price: . The weighted average sale price for the transaction reported was $121.67, and the range of prices were between $121.13 and $122.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document
June 09, 2026 Filed Jun 10, 2026 01:21 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	2,393	$0.00 Strike: $26.49	$0.00	Disclosure SEC source: 0001197350-26-000007 · form4-06102026_010600.xml · derivative · entry 5 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,653 Underlying: Common Stock · 2,393 shares Expires 2034-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4th of the shares vested one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document
June 09, 2026 Filed Jun 10, 2026 01:21 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	2,393	$26.49	$63,390.57	Disclosure SEC source: 0001197350-26-000007 · form4-06102026_010600.xml · nonDerivative · entry 4 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 09, 2026 Filed Jun 12, 2026 01:17 UTC	CERUS CORP CERS · Entity 5431	SaleCommon Stock	20,454	$2.60	$53,180.40	Disclosure SEC source: 0001193125-26-268227 · ownership.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,679 Read SEC document
June 09, 2026 Filed Jun 11, 2026 17:49 UTC	Metagenomi Therapeutics, Inc. MGX · Entity 7270	GrantStock Option (Right to Buy) · Derivative	21,000	$0.00 Strike: $1.23	$0.00	Disclosure SEC source: 0001193125-26-267189 · ownership.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2036-06-08 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document
June 08, 2026 Filed Jun 10, 2026 01:21 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	1,567	$95.12	$149,053.04	Disclosure SEC source: 0001197350-26-000007 · form4-06102026_010600.xml · nonDerivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,788 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026. F4 · price: . The weighted average sale price for the transaction reported was $95.12, and the range of prices were between $94.62 and $95.44. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document
June 08, 2026 Filed Jun 10, 2026 01:21 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	1,175	$93.95	$110,391.25	Disclosure SEC source: 0001197350-26-000007 · form4-06102026_010600.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,355 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026. F3 · price: . The weighted average sale price for the transaction reported was $93.95, and the range of prices were between $93.49 and $94.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document
June 08, 2026 Filed Jun 10, 2026 01:21 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	2,258	$92.84	$209,632.72	Disclosure SEC source: 0001197350-26-000007 · form4-06102026_010600.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,530 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026. F2 · price: . The weighted average sale price for the transaction reported was $92.84, and the range of prices were between $92.485 and $93.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document
June 02, 2026 Filed Jun 2, 2026 23:54 UTC	CERUS CORP CERS · Entity 5431	GrantCommon Stock	60,000	$0.00	$0.00	Disclosure SEC source: 0001193125-26-254116 · ownership.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,133 F1 · shares: Represents RSUs granted pursuant to the Issuer's 2024 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document
May 13, 2026 Filed May 14, 2026 20:25 UTC	Surrozen, Inc./DE SRZN · Entity 6092	GrantDirector Stock Option (right to buy) · Derivative	5,550	$0.00 Strike: $30.14	$0.00	Disclosure SEC source: 0001193125-26-224131 · ownership.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,550 Underlying: Common Stock · 5,550 shares Expires 2036-05-12 F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director. Read SEC document
March 16, 2026 Filed Mar 17, 2026 23:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	7,287	$91.98	$670,242.96	Disclosure SEC source: 0001197350-26-000006 · form4-03172026_070311.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,788 F2 · kind: Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units. Read SEC document
March 15, 2026 Filed Mar 17, 2026 23:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionPerformance Restricted Stock Units · Derivative	13,334	$0.00	$0.00	Disclosure SEC source: 0001197350-26-000006 · form4-03172026_070311.xml · derivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,666 Underlying: Common Stock · 13,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027. F3 · derivative.expiration_date: The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027. Read SEC document
March 15, 2026 Filed Mar 17, 2026 23:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	13,334	Not disclosed	Not disclosed	Disclosure SEC source: 0001197350-26-000006 · form4-03172026_070311.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
January 28, 2026 Filed Jan 30, 2026 23:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantPerformance Restricted Stock Units · Derivative	20,000	$0.00	$0.00	Disclosure SEC source: 0001197350-26-000004 · form4-01302026_060105.xml · derivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: On January 23, 2024, the reporting person was granted performance restricted stock units ("PSUs") which vest upon satisfaction of certain performance criteria. On January 28, 2026, performance criteria were determined to have been met. The shares subject to the PSUs vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027. F4 · derivative.expiration_date: On January 23, 2024, the reporting person was granted performance restricted stock units ("PSUs") which vest upon satisfaction of certain performance criteria. On January 28, 2026, performance criteria were determined to have been met. The shares subject to the PSUs vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027. Read SEC document
January 28, 2026 Filed Jan 30, 2026 23:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantRestricted Stock Units · Derivative	11,760	$0.00	$0.00	Disclosure SEC source: 0001197350-26-000004 · form4-01302026_060105.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,760 Underlying: Common Stock · 11,760 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 28, 2026 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 28, 2026 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document
January 28, 2026 Filed Jan 30, 2026 23:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantStock Option (right to buy) · Derivative	18,140	$0.00 Strike: $100.85	$0.00	Disclosure SEC source: 0001197350-26-000004 · form4-01302026_060105.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,140 Underlying: Common Stock · 18,140 shares Expires 2036-01-27 F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 28, 2026 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document
January 26, 2026 Filed Jan 27, 2026 21:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	1,053	$96.19	$101,290.18	Disclosure SEC source: 0001197350-26-000002 · form4-01272026_040108.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,741 F2 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Read SEC document
January 23, 2026 Filed Jan 27, 2026 21:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionRestricted Stock Units · Derivative	2,667	$0.00	$0.00	Disclosure SEC source: 0001197350-26-000002 · form4-01272026_040108.xml · derivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,666 Underlying: Common Stock · 2,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document
January 23, 2026 Filed Jan 27, 2026 21:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	2,667	Not disclosed	Not disclosed	Disclosure SEC source: 0001197350-26-000002 · form4-01272026_040108.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Read SEC document
January 22, 2026 Filed Jan 23, 2026 22:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	1,421	$93.33	$132,615.11	Disclosure SEC source: 0001197350-26-000001 · form4-01232026_050106.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,127 F3 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Read SEC document
January 21, 2026 Filed Jan 23, 2026 22:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionRestricted Stock Units · Derivative	3,334	$0.00	$0.00	Disclosure SEC source: 0001197350-26-000001 · form4-01232026_050106.xml · derivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,666 Underlying: Common Stock · 3,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F4 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F4 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document
January 21, 2026 Filed Jan 23, 2026 22:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	3,334	Not disclosed	Not disclosed	Disclosure SEC source: 0001197350-26-000001 · form4-01232026_050106.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F2 · balance_after: Includes 269 shares of common stock that were acquired by the Reporting Person on November 10, 2025, pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document
September 12, 2025 Filed Sep 13, 2025 00:00 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	9,578	$76.01	$728,023.78	Disclosure SEC source: 0001415889-25-024462 · form4-09122025_080902.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,945 F2 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document
September 11, 2025 Filed Sep 13, 2025 00:00 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionRestricted Stock Units · Derivative	18,333	$0.00	$0.00	Disclosure SEC source: 0001415889-25-024462 · form4-09122025_080902.xml · derivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,333 Underlying: Common Stock · 18,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F3 · derivative.exercise_date: The restricted stock units vest in a series of three successive equal annual installments beginning on the one-year anniversary of September 11, 2023. F3 · derivative.expiration_date: The restricted stock units vest in a series of three successive equal annual installments beginning on the one-year anniversary of September 11, 2023. Read SEC document
September 11, 2025 Filed Sep 13, 2025 00:00 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	18,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-024462 · form4-09122025_080902.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Read SEC document
August 12, 2025 Filed Aug 13, 2025 00:00 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	2,954	$0.00 Strike: $26.49	$0.00	Disclosure SEC source: 0001415889-25-021522 · form4-08122025_110857.xml · derivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,046 Underlying: Common Stock · 2,954 shares Expires 2034-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares vested one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document
August 12, 2025 Filed Aug 13, 2025 00:00 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	2,954	$26.49	$78,251.46	Disclosure SEC source: 0001415889-25-021522 · form4-08122025_110857.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 11, 2025 Filed Aug 13, 2025 00:00 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	8,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-021522 · form4-08122025_110857.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,236 F1 · price: The weighted average sale price for the transaction reported was $65.50, and the range of prices were between $65.31 and $66.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F2 · balance_after: Includes 290 shares of Common Stock that were acquired by the Reporting Person on May 10, 2025 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:33 UTC	Metagenomi Therapeutics, Inc. MGX · Entity 7270	GrantStock Option (Right to Buy) · Derivative	8,572	$0.00 Strike: $1.57	$0.00	Disclosure SEC source: 0000950170-25-085483 · ownership.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,572 Underlying: Common Stock · 8,572 shares Expires 2035-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document
June 03, 2025 Filed Jun 4, 2025 22:31 UTC	CERUS CORP CERS · Entity 5431	GrantCommon Stock	60,000	$0.00	$0.00	Disclosure SEC source: 0000950170-25-081843 · ownership.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,133 F1 · shares: Represents RSUs granted pursuant to the Issuer's 2024 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document
May 14, 2025 Filed May 15, 2025 21:29 UTC	Surrozen, Inc./DE SRZN · Entity 6092	GrantOption (right to buy) · Derivative	1,333	$0.00 Strike: $6.50	$0.00	Disclosure SEC source: 0001593968-25-000613 · primary_01.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,333 Underlying: Common Stock · 1,333 shares Expires 2035-05-14 F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director. Read SEC document
February 03, 2025 Filed Feb 5, 2025 21:24 UTC	Metagenomi Therapeutics, Inc. MGX · Entity 7270	GrantStock Option (Right to Buy) · Derivative	42,000	$0.00 Strike: $2.51	$0.00	Disclosure SEC source: 0000950170-25-014528 · ownership.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2035-02-02 F1 · derivative.exercise_date: 33.33% of the shares subject to this option shall vest and become exercisable on February 3, 2026, with the remainder vesting in 24 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document
January 23, 2025 Filed Jan 27, 2025 21:49 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionRestricted Stock Units · Derivative	2,667	$0.00	$0.00	Disclosure SEC source: 0001415889-25-002136 · form4-01272025_090146.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,333 Underlying: Common Stock · 2,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F2 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F2 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document
January 23, 2025 Filed Jan 27, 2025 21:49 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	2,667	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-002136 · form4-01272025_090146.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Read SEC document
January 21, 2025 Filed Jan 23, 2025 22:53 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantRestricted Stock Units · Derivative	10,000	$0.00	$0.00	Disclosure SEC source: 0001415889-25-001953 · form4-01232025_100126.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document
January 21, 2025 Filed Jan 23, 2025 22:53 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantStock Option (right to buy) · Derivative	40,000	$0.00 Strike: $47.98	$0.00	Disclosure SEC source: 0001415889-25-001953 · form4-01232025_100126.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-01-20 F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 21, 2025 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document
December 12, 2024 Filed Dec 17, 2024 01:37 UTC	CERUS CORP CERS · Entity 5431	SaleCommon Stock	20,000	$1.79	$35,700.00	Disclosure SEC source: 0000950170-24-136863 · ownership.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,133 F1 · price: The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.78 to $1.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document
November 08, 2024 Filed Nov 14, 2024 21:34 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantCommon Stock	475	$21.05	$9,996.85	Disclosure SEC source: 0001415889-24-026870 · form4-11142024_091128.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,279 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 475 shares by the Reporting Person on November 8, 2024 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document
September 11, 2024 Filed Sep 12, 2024 20:18 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionRestricted Stock Units · Derivative	18,334	$0.00	$0.00	Disclosure SEC source: 0001415889-24-023289 · form4-09122024_080946.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,666 Underlying: Common Stock · 18,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F2 · derivative.exercise_date: The restricted stock units vest in a series of three successive equal annual installments beginning on the one-year anniversary of September 11, 2023. F2 · derivative.expiration_date: The restricted stock units vest in a series of three successive equal annual installments beginning on the one-year anniversary of September 11, 2023. Read SEC document
September 11, 2024 Filed Sep 12, 2024 20:18 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	18,334	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-023289 · form4-09122024_080946.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Read SEC document
August 27, 2024 Filed Aug 28, 2024 23:14 UTC	CalciMedica, Inc. CALC · Entity 7804	GrantDirector Stock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $4.16	$0.00	Disclosure SEC source: 0001415889-24-022508 · form4-08282024_110809.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-08-26 F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 28, 2024. Read SEC document
June 05, 2024 Filed Jun 6, 2024 23:52 UTC	CERUS CORP CERS · Entity 5431	GrantCommon Stock	40,000	$5.00	$200,000.00	Disclosure SEC source: 0001209191-24-005820 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,133 F1 · shares: Represents the number of shares underlying RSUs. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document
June 05, 2024 Filed Jun 7, 2024 00:19 UTC	Surrozen, Inc./DE SRZN · Entity 6092	GrantOption (right to buy) · Derivative	1,333	$0.00 Strike: $11.00	$0.00	Disclosure SEC source: 0001593968-24-000827 · primary_01.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,333 Underlying: Common Stock · 1,333 shares Expires 2034-06-05 F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.